P1.12-20 Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial

Authors :: V. Moreno
Maria Eugenia Olmedo
Arturo Soto-Matos
M.P. Lopez-Criado
Martin Forster
Carmen Kahatt
J.A. Lopez-Vilariño
Emiliano Calvo
R. Nuñez
Source :: Journal of Thoracic Oncology. 13:S581
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Lurbinectedin
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Cohort
Overall survival
Medicine
Doxorubicin
business
medicine.drug

Tools